Author:

Keywords:

diffuse cutaneous leishmaniasis, nitric-oxide synthase, acetyl-l-cysteine, factor-kappa-b, superoxide-dismutase, immune-response, major infection, balb/c mice, diethyldithiocarbamate, survival, Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, DIFFUSE CUTANEOUS LEISHMANIASIS, NITRIC-OXIDE SYNTHASE, ACETYL-L-CYSTEINE, FACTOR-KAPPA-B, SUPEROXIDE-DISMUTASE, IMMUNE-RESPONSE, MAJOR INFECTION, BALB/C MICE, DIETHYLDITHIOCARBAMATE, SURVIVAL, Adjuvants, Immunologic, Animals, Antioxidants, Apoptosis, Cell Survival, Ditiocarb, Humans, Leishmania, Leishmaniasis, Macrophages, Mice, Mice, Inbred BALB C, Mitochondria, Necrosis, Phagosomes, General Science & Technology

Abstract:

Background: Chemotherapy remains the primary tool for treatment and control of human leishmaniasis. However, currently available drugs present serious problems regarding side-effects, variable efficacy, and cost. Affordable and less toxic drugs are urgently needed for leishmaniasis.